Review
doi: 10.14670/HH-25.655.
Targeting the renin angiotensin system for remission/regression of chronic kidney disease
Affiliations
- PMID: 20238303
- DOI: 10.14670/HH-25.655
Item in Clipboard
Review
Targeting the renin angiotensin system for remission/regression of chronic kidney disease
Histol Histopathol.
2010 May.
Abstract
In the last few years great progress has been made in the search for the cellular and molecular mechanisms of chronic kidney disease and its progression to end-stage renal failure. The possibility of remission/regression of chronic nephropathy has become a reality for some patients on therapy based on renin-angiotensin system blockade - an example of how a public health concern can be successfully addressed by translational medicine. This review describes experimental and clinical investigations documenting the advances achieved in the management of chronic kidney diseases by targeting angiotensin II.
Similar articles
-
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].Presse Med. 2002 Nov 9;31(36):1714-20. Presse Med. 2002. PMID: 12467154 Review. French.
-
Dual renin-angiotensin system blockade for nephroprotection.Nephrol Ther. 2017 Apr;13 Suppl 1:S43-S45. doi: 10.1016/j.nephro.2017.02.006. Nephrol Ther. 2017. PMID: 28577742
-
[Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].Wien Klin Wochenschr. 1995;107(1):10-4. Wien Klin Wochenschr. 1995. PMID: 7871784 Review. German.
-
Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?Med Clin (Barc). 2018 Jan 12;150(1):33-38. doi: 10.1016/j.medcli.2017.05.027. Epub 2017 Jun 28. Med Clin (Barc). 2018. PMID: 28668172 English, Spanish. No abstract available.
-
Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.Nephron. 2015;129(1):39-41. doi: 10.1159/000368331. Epub 2014 Dec 16. Nephron. 2015. PMID: 25531311 Review.
Cited by
-
Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.Clin Exp Pharmacol Physiol. 2014 Mar;41(3):227-37. doi: 10.1111/1440-1681.12204. Clin Exp Pharmacol Physiol. 2014. PMID: 24471737 Free PMC article.
-
Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats.Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):451-459. doi: 10.1007/s00210-018-01600-3. Epub 2018 Dec 15. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 30554341
-
Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.PLoS One. 2017 May 19;12(5):e0177451. doi: 10.1371/journal.pone.0177451. eCollection 2017. PLoS One. 2017. PMID: 28542215 Free PMC article.
-
The RenTg mice: a powerful tool to study renin-dependent chronic kidney disease.PLoS One. 2012;7(12):e52362. doi: 10.1371/journal.pone.0052362. Epub 2012 Dec 26. PLoS One. 2012. PMID: 23300650 Free PMC article.
-
Key fibrogenic mediators: old players. Renin-angiotensin system.Kidney Int Suppl (2011). 2014 Nov;4(1):58-64. doi: 10.1038/kisup.2014.11. Kidney Int Suppl (2011). 2014. PMID: 26312151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
